News for Vanda Pharmaceuticals Inc. (0LKB.L)

On June 13, 2025, Stephen Mitchell, a Director at Vanda Pharmaceuticals Inc (VNDA), sold 7,000 shares of the company. Following this transaction, the insider no

PR NewswireWASHINGTON, June 10, 2025 WASHINGTON, June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first

Vanda Pharmaceuticals (VNDA) has commenced its initial human clinical trial to assess VCA-894A, an antisense oligonucleotide therapy. This groundbreaking trial

PR NewswireWASHINGTON, May 27, 2025 WASHINGTON, May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participatio

Vanda Pharmaceuticals (VNDA) to present at the 2025 ASCP Annual Meeting in Scottsdale, Arizona. Dr. Sean R. Chadwick will present pharmacokinetic study

On May 21, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc, purchased 10,000 shares of the company, according to

Vanda Pharmaceuticals (VNDA) is receiving an

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2025 Results Conference Call May 7, 2025 4:30 PM ETCompany ParticipantsKevin Moran - CFOMihael Polymeropoulos -...

\n\nPR NewswireWASHINGTON, May 5, 2025\n\n\n\nWASHINGTON, May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S.

\n Vanda Pharmaceuticals (VNDA) announces the FDA's acceptance of the New Drug Application (NDA) for Bysantiâ\u0084¢ (milsaperidone). FDA decision is scheduled

Vanda Pharmaceuticals (VNDA) has announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application for their product,

Shares of AnaptysBio Inc. (ANAB) are down over 50% from their 52-week high of $41.31, recorded last August, with the stock now hovering around the $20 level..

Vanda Pharmaceuticals (VNDA) has expressed frustration over the U.S. Food and Drug Administration's (FDA) delay in addressing the company's request for a hearin

[url="]Aldeyra Therapeutics, Inc.[/url] (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed t

Vanda's strong financials and product lineup show promise, but management concerns and FDA disputes may hinder growth. Learn more on VNDA stock here.

On March 6, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc, purchased 10,000 shares of the company. Following t

On February 28, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc, purchased 10,000 shares of the company, accordi

On February 27, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc (VNDA), purchased 10,000 shares of the company.

On February 26, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc, purchased 10,000 shares of the company. Followi